UNSPSC 51401501: Bromazepam

This classification denotes a benzodiazepine with the molecular formula C14H10BrN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X015L14V0O, chemically known as 1,3-dihydro-7-bromo-5-(2-pyridyl)-2h-1,4-benzodiazepin-2-one but generally known as bromazepam, which bears US NIH Compound Identifier 2441. European Medicines Agency schedules Bromazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05907MIG.

UNSPSC 51401501 Bromazepam is a Commodity code that, based on recent state and local solicitations, appears to be applied inconsistently and does not reflect a coherent procurement stream. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing — none of which are bromazepam-specific procurement. State and local governments are using this code to tag purchases of emergency medications, pharmacy benefit program services, and bulk pharmaceutical supplies across health departments, human services commissions, and cooperative purchasing alliances, but bromazepam itself does not appear as a line item in any of the posted solicitations. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, with participation from Oregon).

Geographic activity centers on Florida, Texas, and the upper Midwest through cooperative purchasing that spans multiple states. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs; and Minnesota's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The code shows little relevant procurement activity tied to bromazepam specifically, and the mismatch between the code's nominal scope and the actual solicitations suggests either tagging error or that the code serves as a catch-all for pharmaceutical procurement that does not map to narrower commodity lines.